Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Zorn

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Focus on Critical Care|December 1, 1985
When do we stop--or do we?K Zorn
Oncology (Williston Park, N.Y.)|August 20, 2010
Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatmentKristin K Zorn
Gynecologic Oncology|June 19, 2007
Advancing our understanding of endometrial cancer histologic subtypes: should we lump or split?Kristin K Zorn
Oncology (Williston Park, N.Y.)|April 12, 2012
PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality checkKristin K Zorn
Orthopedic Nursing|March 30, 1999
Conducting a workshopS W Selman, K Zorn
Gynecologic Oncology|March 5, 2020
Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of RecommendationsKathleen N Moore, Kristin K Zorn
Frontiers in Oncology|May 6, 2016
Editorial: Inhibiting PARP as a Strategic Target in CancerKristin K Zorn, Christina M Annunziata
Obstetrics and Gynecology|March 3, 2007
Venous thromboembolism in obstetrics and gynecologyThomas C Krivak, Kristin K Zorn
Obstetrics and Gynecology Clinics of North America|December 7, 2007
Strategies for ovarian cancer preventionRebecca Byler Dann, Joseph L Kelley, Kristin K Zorn
DICP : the Annals of Pharmacotherapy|January 1, 1990
The generic drug scandal and its implications for pharmacy professionalsJ A Barone, J L Colaizzi, B K Zorn
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Focus on Critical Care|December 1, 1985
When do we stop--or do we?K Zorn
Oncology (Williston Park, N.Y.)|August 20, 2010
Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatmentKristin K Zorn
Gynecologic Oncology|June 19, 2007
Advancing our understanding of endometrial cancer histologic subtypes: should we lump or split?Kristin K Zorn
Oncology (Williston Park, N.Y.)|April 12, 2012
PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality checkKristin K Zorn
Orthopedic Nursing|March 30, 1999
Conducting a workshopS W Selman, K Zorn
Gynecologic Oncology|March 5, 2020
Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of RecommendationsKathleen N Moore, Kristin K Zorn
Frontiers in Oncology|May 6, 2016
Editorial: Inhibiting PARP as a Strategic Target in CancerKristin K Zorn, Christina M Annunziata
Obstetrics and Gynecology|March 3, 2007
Venous thromboembolism in obstetrics and gynecologyThomas C Krivak, Kristin K Zorn
Obstetrics and Gynecology Clinics of North America|December 7, 2007
Strategies for ovarian cancer preventionRebecca Byler Dann, Joseph L Kelley, Kristin K Zorn
DICP : the Annals of Pharmacotherapy|January 1, 1990
The generic drug scandal and its implications for pharmacy professionalsJ A Barone, J L Colaizzi, B K Zorn
Pageof 8